Autor: |
Barbara Grimes, Adil Daud, Alain Algazi, Simone M. Goldinger, Katy K. Tsai, Adi Nosrati, Thi Dan Linh Nguyen-Kim, Omid Hamid, Kimberly Loo, Reinhard Dummer, Mitchell P. Levesque, Paul C. Tumeh |
Přispěvatelé: |
University of Zurich, Daud, Adil |
Rok vydání: |
2017 |
Předmět: |
|
Zdroj: |
British journal of cancer, vol 116, iss 9 British Journal of Cancer |
Popis: |
Background: Anti-PD-1 therapy has shown significant clinical activity in advanced melanoma. We developed and validated a clinical prediction scale for response to anti- PD-1 monotherapy. Methods: A total of 315 patients with advanced melanoma treated with pembrolizumab (2 or 10 mg kg−1 Q2W or Q3W) or nivolumab (3 mg kg−1 Q2W) at four cancer centres between 2011 to 2013 served as the setting for the present cohort study. Variables with significant association to response on a univariate analysis were entered into a forward stepwise logistic regression model and were given a score based on ORs to calculate a clinical prediction scale. Results: The developed clinical prediction scale included elevated LDH (1 point), age |
Databáze: |
OpenAIRE |
Externí odkaz: |
|